Effects of ARSB and Pembrolizumab on Metastatic Melanoma in B16F10 Mice

A 470 KB PDF report details experiments on the combined effects of Arylsulfatase B (ARSB) and Pembrolizumab in a syngeneic mouse model of metastatic melanoma. The report, authored by Sumit Bhattacharyya and shared under a CC-BY-4.0 license, describes how ARSB treatment interacts with Pembrolizumab to potentially improve therapeutic responses. Findings suggest the combination may increase apoptosis, reduce metalloproteinases and invasiveness, and alter cytokine expression.

Use Cases

• Investigating synergistic mechanisms of action between enzymatic and immunotherapeutic agents based on the described biological pathways.
• Analyzing the role of chondroitin sulfate degradation in tumor progression and treatment response as suggested by the ARSB mechanism.
• Studying apoptosis induction in melanoma cells via increased Constitutive Photomorphogenic 1 (COP1) expression as reported.
• Evaluating changes in cytokine expression profiles following combination therapy as mentioned in the description.

Strengths

• Report is shared under a permissive CC-BY-4.0 license, allowing for broad reuse.
• The description provides a detailed biological rationale for the combination therapy, including specific molecules and pathways like ARSB, C4S, and COP1.

Limitations

• The dataset is a single 470 KB PDF report; the underlying experimental data (e.g., raw measurements, columnar results) is not provided as a structured dataset.
• Row count and column-level documentation are absent, making direct computational analysis impossible without manual extraction.

Provenance

Source

Sumit Bhattacharyya via figshare.

Collection Method

Likely contains results from laboratory experiments using the B16F10 syngeneic mouse model.

Freshness

Last updated 2026-06-01 04:15:11.